Scholarlink

<p>Colorectal Cancer (CRC) progression is a complex and dynamic process closely linked to TET2-mediated DNA demethylation. Distinct from our previous study on TET2 nuclear loss, which can be observed in the whole tumor progression process, the nuclear increase of TET2 was only observed in tumors at the beginning of metastasis. In addition, cells with nuclear TET2 were located at the bottom of the mucosa, which is the invasion front of CRC. All of these results suggested crucial roles of TET2 nuclear increase during tumor progression. Mechanistically, epithelial-mesenchymal transition (EMT) and the activation of the WNT pathway, which is normally recognized as tumor promotion events, were shown to correlate with the cytoplasm-nucleus shuttling of TET2, which is associated with tumor suppression. Nuclear TET2, in turn, mitigated further EMT and WNT activation, suggesting a negative feedback loop between TET2 and the EMT/WNT pathway. Such a negative feedback loop was further supported by single-cell RNA sequencing (scRNA-seq) analysis of both the CRC progression models and the clinical CRC samples. Together, these findings indicate that the tumor inhibition role of EMT/WNT pathway and TET2 is an intrinsic brake on cancer progression, which represents a potential therapeutic target for CRC.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cytoplasm-nucleus shuttling of TET2: an intrinsic brake in colorectal cancer progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Changpeng Li,
  • Fei Meng,
  • Jingcai He,
  • Linna Dong,
  • Yuexian He,
  • Qing Guo,
  • Kerou Zeng,
  • Yanhua Wu,
  • Haofei Ge,
  • Shiyu Chen,
  • Tingting Yang,
  • Yusheng Zhou,
  • Yulu Wang,
  • Lin Liu,
  • Qiwen Ren,
  • Meiai He,
  • Hao Sun,
  • Lining Liang,
  • Lin Guo,
  • Xiaolin Li,
  • Jiahong Hong,
  • Zhenhua Huang,
  • Hui Zheng

摘要

Colorectal Cancer (CRC) progression is a complex and dynamic process closely linked to TET2-mediated DNA demethylation. Distinct from our previous study on TET2 nuclear loss, which can be observed in the whole tumor progression process, the nuclear increase of TET2 was only observed in tumors at the beginning of metastasis. In addition, cells with nuclear TET2 were located at the bottom of the mucosa, which is the invasion front of CRC. All of these results suggested crucial roles of TET2 nuclear increase during tumor progression. Mechanistically, epithelial-mesenchymal transition (EMT) and the activation of the WNT pathway, which is normally recognized as tumor promotion events, were shown to correlate with the cytoplasm-nucleus shuttling of TET2, which is associated with tumor suppression. Nuclear TET2, in turn, mitigated further EMT and WNT activation, suggesting a negative feedback loop between TET2 and the EMT/WNT pathway. Such a negative feedback loop was further supported by single-cell RNA sequencing (scRNA-seq) analysis of both the CRC progression models and the clinical CRC samples. Together, these findings indicate that the tumor inhibition role of EMT/WNT pathway and TET2 is an intrinsic brake on cancer progression, which represents a potential therapeutic target for CRC.